Companies: 10,795·Total market cap: $144.5T
Biotest AG

Biotest AG

BIESFOTCHealthcare
$32.00
+$0.00(+0.00%)
Market Cap$1.6B
P/E Ratio—
52W High$32
52W Low$30.48
Overview

Biotest AG (BIESF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

BIESF · cash on hand · updated Dec 31, 2024

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$119.5M▲ +0.8% vs prior year
FY · as of Dec 31, 2024 · Reported in EUR
Cash & Cash Equiv. (CCE)
$107.8M
cashAndCashEquivalents
Short-Term Investments
$11.7M
shortTermInvestments
YoY Change vs Prior Year
+0.8%
vs prior fiscal year
Latest Quarter
$41.8M
Q1 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2024

Net cash vs debt

Cash & ST Investments$119.5MCash on Hand
Total Debt$597.2MTotal Debt
Net Cash / Net Debt−$477.7MNet Debt Position
Cash vs Debt Ratio
Cash 17%Debt 83%

Biotest AG carries a net debt position of $477.7M. Total debt ($597.2M) exceeds cash on hand ($119.5M). Biotest AG cash vs debt ratio: 17% cash / 83% debt.

Net Cash = Cash & ST Investments − Total Debt$119.5M − $597.2M = −$477.7M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
BIESF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2024Latest$119.5M+0.8%
Dec 31, 2023$118.5M-13.3%
Dec 31, 2022$136.6M+16.3%
Dec 31, 2021$117.5M+31.7%
Dec 31, 2020$89.2M+4.1%
BIESF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Biotest AG
Biotest AGYOU
BIESF
$119.5M7.5%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Biotest AG (BIESF) cash on hand as of December 31, 2024 is $119.5M, comprising $107.8M in cash and cash equivalents (CCE) plus $11.7M in short-term investments — reported as Biotest AG cash and short-term investments on the balance sheet (10-K filing). Also referred to as Biotest AG cash reserves or cash position.

Biotest AG annual cash on hand history shows increased +0.8% in 2024: increased +0.8% in 2024. Biotest AG cash reserves in 2024 reflect the company's capital allocation strategy.

Biotest AG carries total debt of $597.2M against cash of $119.5M, resulting in a net debt position of -$477.7M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

BIESF cash on hand · 5 questions

As of December 31, 2024, Biotest AG (BIESF) has $119,500,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $107,800,000 in cash and cash equivalents (CCE) plus $11,700,000 in short-term investments. Latest quarter (March 31, 2025): $41,800,000. Data sourced from the annual 10-K filing via FMP.

BIESF cash on handBIESF cash reservesBIESF cash 2024how much cash does BIESF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Biotest AG · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2024